Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes POST Worsening Heart Failure
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Cardiovascular disorders; Heart failure; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SOLOIST; SOLOIST-WHF
- Sponsors Lexicon Pharmaceuticals
- 13 Nov 2023 Results evaluating the cost-effectiveness of sotagliflozin in all patients and those with preserved (HFpEF greater than 50%) and reduced (HFrEF less than 50%) ejection fraction, presented at the American Heart Association Scientific Sessions 2023
- 13 Nov 2023 Results quantifying the financial impact on health systems of adopting sotagliflozin relative to standard of care (SoC) for treating patients with HF , presented at the American Heart Association Scientific Sessions 2023
- 02 Nov 2023 According to a Lexicon Pharmaceuticals media release, data from this study will be presented at the American Heart Association Scientific Sessions 2023, November 11-13, 2023, at the Pennsylvania Convention Center in Philadelphia, PA.